PressMay 8, 2023 Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
PressMay 8, 2023 MIND CURE AND LNG ENERGY GROUP ENTER INTO ARRANGEMENT AGREEMENT WITH RESPECT TO PREVIOUSLY ANNOUNCED BUSINESS COMBINATION TRANSACTION
PressMay 5, 2023 First Patient Dosed in Beckley Psytech’s Phase IIa Study of BPL-003 for Treatment Resistant Depression
PressMay 4, 2023 Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development
PressMay 4, 2023 COMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023
PressMay 2, 2023 Blackhawk and Mindbio Therapeutics Corp. (formerly, 1286409 B.C. LTD.) Announce Completion of Plan of Arrangement
PressMay 2, 2023 Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A
PressMay 2, 2023 PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease
PressMay 2, 2023 Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
PressMay 2, 2023 Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19
PressApril 28, 2023 atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
PressApril 27, 2023 PSYC Explores the Boundaries of Psychedelics and Society with New Video Series, “PSYC Taboo”
PressApril 27, 2023 Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
PressApril 26, 2023 Mindbloom Announces Partnership with SHIFT To Offer Affordable At-Home Ketamine Therapy To Its Employees
